A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

NCT07023315 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

760

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG: Cadonilimab
DRUG: SOX chemotherapy
DRUG: Placebo

Sponsor

Akeso